How Do GLP-1 Weight Loss Injections Work?

You have almost certainly heard of Mounjaro or Wegovy by now. These injectable weight loss treatments have become some of the most talked-about medications in the UK, and for good reason: the clinical results behind them are genuinely significant. But for many people considering treatment, the question remains: what are these injections actually doing inside your body?

GLP-1, GIP, receptor agonist, tirzepatide, semaglutide. The terminology can make these treatments feel complicated or clinical when they are not. At their core, they work by amplifying signals your body already produces naturally, signals that tell you that you are full, that you have eaten enough, and that your blood sugar is under control.

This article explains exactly how these medications work, what you can realistically expect from treatment, and what the differences between the main options are, all in plain English.

What is a GLP-1 receptor agonist?

GLP-1 stands for glucagon-like peptide-1. It is a hormone your gut produces naturally in response to eating. When you have a meal, your body releases GLP-1 to signal to the brain that food has arrived, slow digestion, reduce appetite, and help regulate blood sugar. Think of it as one of your body's built-in brakes on hunger.

GLP-1 receptor agonists are medications that mimic this hormone. They bind to the same receptors in the body that natural GLP-1 activates, but they do so more powerfully and for much longer. Where your body's own GLP-1 breaks down within minutes, injectable GLP-1 medications are formulated to remain active for a full week from a single dose. [1]

The result is a sustained amplification of signals your body already knows how to produce. Rather than introducing something entirely foreign, these treatments work with your biology.

"GLP-1 treatments work by mimicking natural hormones that help regulate appetite, fullness, and blood sugar levels. In simple terms, they help people feel satisfied with less food and reduce the constant 'food noise' that can make weight management so challenging.

One of the most important things I tell patients is that obesity is not simply about willpower. Many people have spent years blaming themselves despite doing everything they can to lose weight. GLP-1 treatments help address some of the biological drivers of obesity, giving patients the support they need to make sustainable lifestyle changes and improve their long-term health."

— Dr Saira Bano, GP with a special interest in metabolic health and obesity at SwiftDoctor

How do GLP-1 injections affect appetite and hunger?

GLP-1 medications affect appetite through two main pathways, and understanding both helps explain why so many patients report a noticeably different relationship with food during treatment.

The first is gastric emptying. These medications slow down how quickly food moves from your stomach into the digestive tract. This means you feel fuller for longer after a meal, and that fullness signals to your brain more effectively that your energy needs have been met. [1]

The second is direct action on the brain. GLP-1 receptors are found in areas of the brain involved in appetite regulation, particularly the hypothalamus. By activating these receptors, GLP-1 medications reduce both the intensity of hunger and what many patients describe as "food noise", the constant background preoccupation with food, cravings, and thoughts about eating that can make managing weight feel exhausting. For many people, the reduction in this mental load is one of the most significant and unexpected effects of GLP-1 treatment.

How does Mounjaro work?

Mounjaro (tirzepatide) is what is known as a dual agonist. Where earlier GLP-1 medications act on a single receptor, Mounjaro targets two: the GLP-1 receptor and the GIP receptor. GIP stands for glucose-dependent insulinotropic polypeptide, another naturally occurring gut hormone involved in appetite regulation and fat metabolism. [2]

In practical terms, this dual action means that Mounjaro is activating two complementary hormonal pathways simultaneously. The combination appears to produce a stronger appetite-suppressing effect and a more pronounced metabolic response than targeting GLP-1 alone. In the SURMOUNT-1 clinical trial, participants taking tirzepatide at the highest dose lost an average of 22.5% of their body weight over 72 weeks, a result described by researchers as an unusually substantial degree of weight reduction for a medication in this class. [2]

Mounjaro is administered as a once-weekly subcutaneous injection. It is currently approved in the UK for weight management in adults with a BMI of 30 or above, or 27 or above with at least one weight-related health condition.

How does Wegovy work?

Wegovy (semaglutide) is a GLP-1 receptor agonist administered as a once-weekly injection. It works by mimicking the GLP-1 hormone to reduce appetite, slow gastric emptying, and regulate blood sugar, using the same fundamental mechanism described above. [1]

Wegovy is used at a higher dose than the diabetes formulation of semaglutide (Ozempic), having been developed and approved specifically for weight management. In the STEP 1 clinical trial, participants taking Wegovy lost an average of around 15% of their body weight over 68 weeks. [3]

At SwiftDoctor, doses are only increased if a patient has reached a plateau in their weight loss and needs a higher dose to continue progressing. This approach prioritises tolerability and means patients are not pushed onto higher doses before they are ready or before there is a clinical reason to do so.

What happens in the body during GLP-1 treatment?

The first few weeks of treatment are typically a period of adjustment. Most patients notice a reduction in appetite and hunger relatively early, often within the first week or two of starting. The intensity of food cravings tends to reduce, and many people find they feel satisfied after eating smaller portions than they would previously have managed.

Some patients experience nausea, particularly during the early weeks or after a dose adjustment. This is a very common response and reflects the medication's effect on gastric emptying. For most people it is mild and temporary, settling as the body adjusts. Eating smaller meals, avoiding rich or fatty foods, and staying hydrated can all help manage this. [4]

Meaningful weight loss typically becomes apparent over weeks to months rather than days. GLP-1 treatment is not a rapid fix. It works gradually and consistently, and the results tend to compound over time as appetite changes support sustained dietary changes. Behaviour change alongside medication, including attention to food quality and physical activity, plays an important role in maximising and maintaining results.

How long does it take for GLP-1 injections to work?

Most patients notice appetite and hunger changes within the first one to two weeks of starting treatment. These early effects, while encouraging, are not the same as weight loss, which takes longer to become visible on the scales.

Clinically meaningful weight loss typically begins to become apparent from around four to eight weeks, with results continuing to develop over the course of several months. At SwiftDoctor, doses are only increased when a patient has reached a plateau in their weight loss and a higher dose is clinically appropriate, rather than as a routine escalation.

It is also worth being clear that individual results vary. Factors including starting weight, dietary habits, activity levels, and individual physiology all influence outcomes. The clinical trial averages represent results across large populations, and your own experience may differ.

Are GLP-1 weight loss injections safe?

GLP-1 medications are licensed prescription treatments, and in the UK they are only available through regulated clinical pathways. This means any patient starting treatment should be assessed by a qualified clinician to confirm they are an appropriate candidate.

The most commonly reported side effects are gastrointestinal, primarily nausea, vomiting, constipation, and diarrhoea. These are typically most noticeable in the early weeks of treatment or following a dose change, and tend to improve as the body adjusts. [4]

GLP-1 medications are not appropriate for everyone. They are generally not recommended for people with a personal or family history of certain thyroid conditions or pancreatitis, among other contraindications, which is why clinical assessment before prescribing is an essential part of responsible treatment. Ongoing monitoring throughout treatment is equally important. [4]

Frequently Asked Questions 

Do GLP-1 medications change your relationship with food? 

Many patients describe this as one of the most meaningful shifts during treatment. The reduction in food noise, the constant mental preoccupation with eating and cravings, can feel quite profound for people who have spent years managing weight through willpower alone. For many, it is the first time hunger has felt manageable rather than overwhelming.

Can GLP-1 injections help with emotional eating? 

Indirectly, yes. By reducing the intensity of cravings and food preoccupation, many patients find that impulse-driven or emotionally triggered eating becomes easier to manage. The medication does not address the psychological roots of emotional eating directly, but the reduction in food noise can create space to build healthier habits alongside treatment.

Do I need to change my diet while on a GLP-1 injection? 

You are not required to follow a specific diet, but the results are meaningfully better when medication is combined with dietary changes. Reduced appetite makes it easier to eat smaller, more nutritious meals, and leaning into that rather than eating the same volume as before tends to produce stronger outcomes.

What happens if I stop taking a GLP-1 injection? 

Appetite typically returns to its previous levels once treatment stops, and some weight regain is common. This is why GLP-1 treatment is considered a long-term intervention rather than a short course, and why any decision to stop should be made with your clinician rather than independently.

Is a prescription required for GLP-1 weight loss injections in the UK? 

Yes. GLP-1 weight loss injections are prescription-only medications in the UK and cannot be purchased over the counter. They must be prescribed by a qualified clinician following an assessment to confirm you are a suitable candidate. SwiftDoctor offers a fast, discreet online consultation process through which eligible patients can access these treatments.

Disclaimer & Editorial Standards

The health-related content published on this site is based on credible scientific sources and is periodically reviewed to ensure accuracy and relevance. Although we aim to reflect the most current medical knowledge, the material is meant for general education and awareness only.

The information on this site is not a substitute for professional medical advice. For any health concerns, please speak with a qualified medical professional. By using this information, you acknowledge responsibility for any decisions made and understand we are not liable for any consequences that may result.

Any third-party brands or services referenced on this site are included for informational purposes only; we are entirely independent and have no affiliation, partnership, or collaboration with any companies mentioned.

Sources

1. Nauck, M.A. & Meier, J.J. (2019). Management of endocrine disease: Are all GLP-1 agonists equal in the treatment of type 2 diabetes? European Journal of Endocrinology, 181(6), R211–R234. https://doi.org/10.1530/EJE-19-0566

2. Jastreboff, A.M. et al. (2022). Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine, 387, 205–216. https://doi.org/10.1056/NEJMoa2206038

3. Wilding, J.P.H. et al. (2021). Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine, 384, 989–1002. https://doi.org/10.1056/NEJMoa2032183

4. Electronic Medicines Compendium (2024). Wegovy 0.25 mg–2.4 mg solution for injection: Summary of Product Characteristics. Novo Nordisk. https://www.medicines.org.uk/emc/product/13616/smpc